How drug access works in Canada
The road a new drug travels in Canada — Health Canada review, Canada's Drug Agency assessment, pCPA price talks, provincial coverage — and where pancreatic cancer drugs stall.
Approval and access are not the same thing in Canada. A new drug can be cleared for sale here and still be years away from the patients who need it, because approval and public funding are separate decisions, made by different organizations, on different timelines. This page explains the road a drug travels — and the routes patients use while they wait.
Tracking a specific drug? The foundation's drug approval transparency tracker follows where individual pancreatic cancer drugs stand in the process described below.
The four steps
Before a new drug can be approved and publicly funded in Canada, it passes through four separate steps. A drug can clear step 1 and still take years to reach step 4 — and some never do. The timing and order of the steps can vary, and some steps happen at the same time.
| Step | Who decides | What they decide | Typical time |
|---|---|---|---|
| 1. Health Canada review | Health Canada | Can the drug be sold in Canada? | 300-day target (180 days for priority review) |
| 2. Public-funding assessment | Canada's Drug Agency (INESSS in Quebec) | Is it good value for public money? | Recent median about 206 days; a streamlined process targeting 180 days began in 2026 |
| 3. Price negotiations | pan-Canadian Pharmaceutical Alliance (pCPA) | What will public plans pay? | Roughly 4 months to decide to negotiate, plus 4–5 months at the table |
| 4. Coverage decisions | Each provincial, territorial and federal drug plan | Will this plan fund it, and for whom? | Months per plan; about two years on average from approval to funding for recent cancer drugs |
Step 1: Health Canada review
Health Canada, the federal department that regulates drugs, assesses the manufacturer's evidence on safety, effectiveness and manufacturing quality. If the answer is yes, the drug receives a Notice of Compliance and a Drug Identification Number (DIN), and it can legally be sold in Canada. The target is 300 days for a standard review; drugs for serious or life-threatening conditions with few existing treatments can get priority review, with a target of 180 days.
Approval decides only that a drug can be sold. It does not decide who pays — everything about funding happens in the steps that follow.
Step 2: Public-funding assessment
Canada's Drug Agency — formerly CADTH, and INESSS in Quebec — reviews the drug's clinical benefits and value for money, and makes a funding recommendation to the public drug plans. The recommendation is advice, not a decision, and it comes in three broad forms: fund it, don't fund it, or fund it with conditions — for example, only for certain patients, or only if the price comes down. In practice, almost every positive recommendation carries conditions. This work can overlap with Health Canada's review, so the two clocks often run at the same time.
Step 3: Price negotiations
The pan-Canadian Pharmaceutical Alliance, or pCPA — the provinces, territories and federal government negotiating together — may negotiate pricing and other terms with the manufacturer. One national negotiation replaces thirteen separate ones, and the agreed price is confidential. If negotiations succeed, the pCPA issues a letter of intent and each plan can move to list the drug. If they fail, public funding usually stops there. This step has no fixed deadline and is the least predictable: recent data puts the median at roughly four months for the pCPA just to decide whether to negotiate, and another four to five months at the table.
Step 4: Coverage decisions
Finally, each individual public drug plan — every province and territory, plus federal plans for populations such as veterans and First Nations — decides whether to fund the drug and who qualifies. Even after a successful negotiation, listing happens plan by plan, on each plan's own timeline and terms. That is why access to the same approved drug can differ depending on where a patient lives.
Getting a drug before the steps finish
Until the four steps are complete, the routes to a new drug are the early ones:
- Clinical trials. Enrolling in a trial can provide access while a drug is still being studied. See planning ahead for clinical trials.
- The Special Access Programme. Health Canada's Special Access Programme (SAP) lets a treating doctor request an unauthorized drug for a specific patient with a serious or life-threatening condition, when usual treatments have failed, are unsuitable, or are unavailable — if the manufacturer agrees to supply it.
- Private insurance and manufacturer programs. After Health Canada approval but before public funding, some patients reach a drug through private insurance or a manufacturer patient-support program. The foundation's financial support resources explain what help exists.
Where pancreatic cancer drugs get stuck
Two pinch points matter most. Step 3 has no deadline, so a drug can sit in confidential negotiations with no public account of its status — the transparency problem the foundation's tracker exists to document. And step 4 repeats the decision in every province and territory, which is how a single national process produces different access depending on a patient's postal code. The foundation's provincial report card grades each jurisdiction on drug coverage, and its province guides collect the practical support available where you live.
Keep reading
- Is Daraxonrasib available in Canada? — the foundation's flagship explainer, following one drug through this system.
- Daraxonrasib just doubled survival in pancreatic cancer — here's what that means for Canadians
- What I heard at Canada's Drug Agency Symposium 2026 — and what it means for pancreatic cancer families.
- Drug approval transparency — the tracker, and what the foundation is asking to change.